CMS posts 2014 clinical quality measures

The Centers for Medicare & Medicaid Services (CMS) has posted the 64 clinical quality measures (CQMs) that eligible professionals and hospitals will be required to report beginning in 2014.

Beginning in 2014, the reporting of CQMs will change for all providers. EHR technology that has been certified to the 2014 Edition standards and certification criteria will have been tested for enhanced CQM-related capabilities, eligible professionals (EPs), eligible hospitals and critical access hospitals (CAHs) will be required to report using the new 2014 criteria regardless of whether they are participating in Stage 1 or Stage 2 of the Medicare and Medicaid EHR Incentive Programs.

Although CQM reporting has been removed as a core objective for both EPs and eligible hospitals and CAHs, all providers are required to report on CQMs to demonstrate Meaningful Use. Eligible professionals are required to report on nine of the measures, of which at least three must cover specific domains. Hospitals must report on 16 of 29 CQMs with at least three in specific domains.

More information about the CQMs and reporting them is available on the CMS website.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.